Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Advair expanded COPD claim "not approvable"

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

GlaxoSmithKline's sNDA for Advair Diskus (fluticasone/salmeterol inhalation powder) 500/50 mcg is "not approvable" for an expanded chronic obstructive pulmonary disease indication. FDA's Aug. 6 letter questions how the higher-dose form of the long-acting beta agonist bronchodilator compares with the approved Advair 250/50 mcg strength. GSK does not have head-to-head data comparing the two formulations, the firm tells Pharmaceutical Approvals Monthly. FDA's Pulmonary-Allergy Drugs Advisory Committee issued a mixed review of the product May 1, voting 9-2 that GSK's pivotal trial failed to provide "substantial convincing evidence" that the 500/50 dose increased COPD survival...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS003637

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel